Plain-English translation of NCT05974774 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial compares two approaches to treating advanced prostate cancer that has spread to other parts of the body. One group continues hormone-blocking medications continuously, while the other group stops treatment after their cancer responds well and restarts it only if needed based on blood tests. The study uses a combination of androgen deprivation therapy and AR pathway inhibitors (such as abiraterone, enzalutamide, apalutamide, or darolutamide) to control the cancer.
Current standard treatment requires taking these medications continuously, which can cause significant side effects like fatigue, sexual dysfunction, bone loss, and heart problems. This trial explores whether giving patients scheduled breaks from the medication can improve their quality of life and reduce these side effects while still keeping the cancer under control.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group continues taking the hormone-blocking medications continuously as usual. The other group stops taking the medication after their cancer has responded well and only restarts it if their PSA blood test shows the cancer is growing again. You will have regular clinic visits and PSA blood tests to monitor your cancer status, allowing doctors to catch any regrowth early and decide when to restart treatment if needed.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Denmark
France